- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | NYRADA INC.: Change of Director's Interest Notice - ID | 1 | ASX | ||
| So | NYRADA INC.: Notification of cessation of securities - NYR | - | ASX | ||
| 13.01. | NYRADA INC.: Cleansing Statement | 2 | ASX | ||
| 13.01. | NYRADA INC.: Application for quotation of securities - NYR | 2 | ASX | ||
| 12.01. | NYRADA INC.: Cleansing Statement | 1 | ASX | ||
| NYRADA INC Aktie jetzt für 0€ handeln | |||||
| 12.01. | NYRADA INC.: Application for quotation of securities - NYR | 1 | ASX | ||
| 08.01. | Nyrada's Phase IIa Clinical Trial for Heart Attack Treatment Approved | 2 | Finance News Network | ||
| 08.01. | NYRADA INC.: Nyrada Phase IIa Clinical Trial Approved to Commence | 3 | ASX | ||
| 06.01. | NYRADA INC.: Cleansing Statement | 1 | ASX | ||
| 06.01. | NYRADA INC.: Application for quotation of securities - NYR | 1 | ASX | ||
| 31.12.25 | NYRADA INC.: Cleansing Statement | 1 | ASX | ||
| 31.12.25 | NYRADA INC.: Application for quotation of securities - NYR | 4 | ASX | ||
| 21.12.25 | NYRADA INC.: Change of Director's Interest Notice - ID | - | ASX | ||
| 18.12.25 | NYRADA INC.: Upcoming Expiry of Unlisted Options | - | ASX | ||
| 09.12.25 | NYRADA INC.: Change of Director's Interest Notice - RW | - | ASX | ||
| 09.12.25 | NYRADA INC.: Change of Director's Interest Notice - JM | - | ASX | ||
| 09.12.25 | NYRADA INC.: Change of Director's Interest Notice - MF | - | ASX | ||
| 09.12.25 | NYRADA INC.: Change of Director's Interest Notice - CC | - | ASX | ||
| 09.12.25 | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 09.12.25 | NYRADA INC.: Application for quotation of securities - NYR | - | ASX |
1 2 3 4 5 Weiter >>
91 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 48,000 | +22,28 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Qiagen beim fairen Aktienwert von 50 Euro auf "Kaufen" belassen. Der Diagnostikspezialist habe seine Mittelfristziele für Wachstumstreiber... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 324,08 | 0,00 % | Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus | ||
| ARCELLX | 72,17 | 0,00 % | Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials | ||
| APOGEE THERAPEUTICS | 82,04 | +1,57 % | Apogee Therapeutics auf Rekordhoch: Aktie erreicht 81,0 USD | ||
| COGENT BIOSCIENCES | 39,900 | +2,47 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 70,93 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 90,85 | 0,00 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence | ||
| NURIX THERAPEUTICS | 18,240 | 0,00 % | BTIG reiterates Buy rating on Nurix stock with $30 price target | ||
| BEAM THERAPEUTICS | 30,965 | 0,00 % | Beam Therapeutics stock maintains Buy rating at H.C. Wainwright on FDA alignment | ||
| DAY ONE BIOPHARMACEUTICALS | 12,120 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| NUVALENT | 105,93 | 0,00 % | Nuvalent, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,395 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| ALUMIS | 26,050 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| ERASCA | 9,805 | 0,00 % | Erasca-Aktie gibt nach geplanter Kapitalerhöhung über 150 Mio. US-Dollar nach | ||
| IMMUNITYBIO | 5,500 | +0,59 % | Fiserv, Western Digital & ImmunityBio: Lohnen sich diese Aktien jetzt? |
Das Unternehmen NYRADA INC CDIS kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NYRADA INC CDIS finden Sie auf Wallstreet Online.